Form 4: Pulse Biosciences Director Mahkam Zanganeh Acquires Stock Options

Director Mahkam Zanganeh acquired stock options for Pulse Biosciences, Inc. on June 6, 2024.

Summary

• On June 6, 2024, Mahkam Zanganeh, a director of Pulse Biosciences, Inc., acquired stock options.
• Zanganeh acquired options to purchase 20,000 shares at an exercise price of $14.55, vesting monthly over one year starting July 6, 2024.
• Additionally, Zanganeh acquired options to purchase 8,247 shares at an exercise price of $14.55, vesting quarterly over one year starting September 5, 2024.
• Following these transactions, Zanganeh directly owns options for 28,247 shares of Pulse Biosciences common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider activity and can be used by investors to gauge sentiment.

Stakeholder Impact

• Shareholders may view the option grants as an incentive for the director to work towards increasing shareholder value.

Key Dates